ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders

Rhea-AI Summary

ARCA biopharma (Nasdaq: ABIO) announced a change in the location of its 2020 Annual Meeting of Stockholders to its Westminster, CO offices due to COVID-19 restrictions. Scheduled for December 10, 2020, the meeting will follow health guidelines with limited seating and mandatory face coverings. Attendees unable to join in person will have remote participation options. For further details, the company's Notice of 2020 Annual Meeting and Proxy Statement is available on their website. ARCA is focused on developing therapies for cardiovascular diseases and RNA virus-related conditions, including COVID-19.

Positive

• None.

Negative

• Uncertainty regarding sufficient financial resources for ongoing operations and development of AB201.
• Potential challenges in raising capital on acceptable terms for continued development.
• Risks associated with drug discovery and regulatory approval processes.

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices located at 10170 Church Ranch Way, Suite 100, Westminster, CO 80021, approximately one-quarter mile from the previously noticed location. The meeting location change is due to the COVID-19 related unavailability of the previously noticed meeting location.

Due to the COVID-19 pandemic, seating capacity will be limited to comply with guidelines promulgated by relevant public health authorities. Social distancing will be observed at all times during the meeting and each attendee will be required to wear a protective face covering. Should more participants want to join the meeting than available seating capacity, those participants will be provided the opportunity participate in the meeting via remote means.

Further information regarding the annual meeting matters is available in the company's Notice of 2020 Annual Meeting and Proxy Statement filed on October 28, 2020, which is available by clicking on “SEC Filings” under the “Investors” tab on the company's website.

About ARCA biopharma
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing Gencaro^TM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential pharmacogenetic treatment for atrial fibrillation in patients with heart failure. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding potential future development plans for AB201, the expected features and characteristics of AB201, AB201’s potential to treat COVID-19, or any other RNA virus associated disease, and future treatment options for patients with COVID-19. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of AB201 or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended December 31, 2019, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:
Derek Cole
720.940.2163
derek.cole@arcabio.com

FAQ

What is the date for ARCA biopharma's 2020 Annual Meeting of Stockholders?

The meeting is scheduled for December 10, 2020.

Where will ARCA biopharma's stockholder meeting be held?

The meeting will be held at ARCA's offices in Westminster, CO.

What precautions are being taken for the Annual Meeting due to COVID-19?

Seating will be limited, social distancing will be observed, and attendees must wear face coverings.

Can more participants join ARCA's Annual Meeting if seated capacity is exceeded?

Yes, participants will be able to join the meeting remotely.

What therapeutic areas is ARCA biopharma focusing on?

ARCA is developing therapies for cardiovascular diseases and RNA virus-related conditions, including COVID-19.

What is the significance of AB201 for ARCA biopharma?

AB201 is being developed as a potential treatment for diseases caused by RNA viruses, with an initial focus on COVID-19.